{"page":{"totalFilteredElements":7},"studies":[{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)","eudractNumber":"2024-511838-12-00","id":9817,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06598306","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2024-11-26T08:36:39+01:00","shortTitle":"AMG 757 20230298 (DeLLphi-308)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability,\nPharmacokinetics, and Efficacy of Tarlatamab in Combination\nwith ZL-1310 with or without Anti-PD-L1 in Participants with\nSmall Cell Lung Cancer","eudractNumber":"2025-522888-15-00","id":11558,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":null,"phase":{"id":"ph_6","name":"Phase IB"},"recruitmentStart":"2026-05-28T12:23:31+02:00","shortTitle":"AMG 757 20250114 (DeLLphi 313)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"DAREON&#174;-Lung-1: A Phase III multi-center,\nopen-label, randomised trial of intravenous obrixtamig in combination with\natezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and\netoposide as first-line treatment in patients with extensive-stage small cell\nlung cancer","eudractNumber":"2025-520565-51-00","id":11554,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-07-28T12:21:28+02:00","shortTitle":"BI - 1438-0012 DAREON Lung 1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Klinische Plattform zur Erforschung molekularer Ver&#228;nderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs","eudractNumber":null,"id":3383,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02622581","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2015-08-16T08:23:05+02:00","shortTitle":"CRISP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC (DuCoRa-SCLC)","eudractNumber":"2022-001822-31","id":10150,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-01-07T08:54:18+01:00","shortTitle":"DuCoRa-SCLC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","eudractNumber":null,"id":4357,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05934032","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-01-01T12:00:40+01:00","shortTitle":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Netzwerk Onkologie (NO) - Therapiebegleitende Darstellung des Versorgungsalltages in der integrativen Onkologie<div><br /></div><div>DRKS:&#160;DRKS00013335<br /></div><div><br /></div><div>Retrospektiv</div>","eudractNumber":null,"id":12273,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-22T08:21:56+02:00","shortTitle":"Netzwerk Onkologie (NO)","therapeutical":false,"therapyLines":[]}]}